At the depths of the ocean, where the environment is pitch-black, creatures such as fish have developed special air sacs, gill organs, luminescent bodies... These unique physiological characteristics enable deep-sea fish to gradually adapt to extreme conditions, survive for extended periods, and achieve species evolution.

Adaptive evolution, such as that seen in deep-sea fish, is not limited to the field of biology; it is also ubiquitous in the modern economic and social landscape. Facing the ever-changing market environment, evolving to meet these changes has become crucial for businesses to maintain their vitality in times of transformation. Haier Group is a prime example of this, having become a leader in the home appliance market. Instead of resting on its laurels, Haier Group ventured into the high-growth health sector and, with innovative strategies, emerged as a top player in the industry. Over the years, its ability to synchronize with the times and continuously evolve has been key to its sustained vitality.

This year, Haier Group's exploration in the field of big health is accelerating. In [month], Haier Group announced the completion of strategic investment in Shanghai Laishi, and the number of listed companies under the "Yingkang Yisheng" big health sector of Haier has risen to three. In mid-[month], Yingkang Yisheng was selected into the "Breakthrough" quadrant of the ecological brand at the (3rd) Ecological Brand Conference.

With Haier Group's continuous expansion in the health sector, a "big health" medical industry worth over 10 billion yuan has emerged, covering biotechnology, clinical medicine, and biotechnology. Unlike other competitors in the big health field, Yingkang Yisheng has chosen to rely on its innovative genes, shifting from focusing on the quality of life to the quality of life itself, and building a big health industry ecosystem driven by technology and digital intelligence. Under this ecosystem with zero boundaries, more new products, new scenarios, and new species are constantly being incubated and implemented. It is reported that from a certain date to another, Yingkang Yisheng will participate in the CIIE for the fifth time, with over 100% of the exhibits being world premieres and first exhibitions.

The big health map surfaced

Internally, drive the self-evolution of each self-organizing entity through the "Ren Dan He Yi" model; externally, promote the maximization of value for all ecosystem parties through the "Eco-Zero Boundary" approach. Committed to realizing the vision of "All People Enjoying a Prosperous Life". At the (Third) Ecological Brand Conference, Liu Gang, General Manager of Operations at Ying Kang Life, introduced the future blueprint for the healthcare sector of Haier Group.

Corresponding to this speech is Haier Group's long-standing practice in the field of big health.

As early as the year, Haier Group established Haier Biomedical, a company specializing in low-temperature medical storage equipment, gradually covering the full product line from -196℃ to 8℃ with its low-temperature refrigeration advantages; in 2019, Haier Group acquired the listed company Xingpu Medical for 1.88 billion yuan, which was later renamed Yingkang Life. The independently developed gamma knife products received market acclaim, and the initial framework of the healthcare sector began to take shape.

However, despite the continuous efforts, Haier Group's practices in the healthcare sector are still in the exploratory stage, with significant room for development. The two listed companies under "Yingkang Yisheng" have annual revenues of less than 1 billion yuan. Yingkang Life reported revenues of 5.25 billion yuan and net profits of 1.44 billion yuan; Haier Biomedical reported revenues of 2.53 billion yuan and net profits of 840 million yuan. Within Haier Group, the healthcare sector, although one of the three core strategic business units alongside smart home living and industrial internet, has a relatively large gap in revenue compared to Haier Smart Home, which has already surpassed 100 billion yuan in revenue.

Recently, after Haier Group announced the completion of strategic investment in Shanghai RAAS, this predicament may be broken. Based on annual performance, the combined revenue of Haier Biomedical, Yingkang Life, and Shanghai RAAS has approached one billion yuan, ranking among the top in the industry.

The strategic layout of Haier Group in the healthcare sector is becoming increasingly clear. The focus in the field of bioscience is primarily on Haier Biomedical, a listed company, which provides comprehensive digital scenario solutions such as smart laboratories and smart compliant pharmaceutical manufacturing for pharmaceutical and biotech enterprises, universities, research institutions, and hospitals. In the clinical medicine sector, the layout is centered on Yingkang Life, another listed company, which uses IoT technology to break down healthcare boundaries and constructs a human-centric "prevention, diagnosis, treatment, and rehabilitation" health management system throughout the entire life cycle. In the biotechnology sector, the focus is on the recently acquired listed company Shanghai RAAS, which, while continuing to develop its existing blood products, is also intensifying exploration into cutting-edge technologies such as biopharmaceuticals.

These three major sectors, seemingly complex and isolated from each other, are actually cleverly interconnected, jointly supporting the large health industry ecosystem of Yingkang Yisheng. Taking the blood ecosystem as an example, after acquiring Shanghai Lai Shi, it will achieve a seamless connection from upstream blood plasma collection, to midstream blood product production, and downstream application scenarios, forming a closed loop. In other words, in the future, blood products may be manufactured by Shanghai Lai Shi, stored at low temperatures and managed intelligently by Haier Biomedical, and even subsequently used within Yingkang Life's medical institutions.

Six months after the upgrade of the big health sector, initial results have already begun to show. It is reported that from [specific dates], the 7th China International Import Expo (CIIE) is about to commence. This year, Yingkang Life will present under the theme "Beyond Boundaries, Intelligent Future," showcasing its core scenarios, multiple star products, and digital intelligence solutions. Among them, the globally pioneering fourth-generation biobank "Ark of Life," the targeted temperature management system for vascular diseases facing stroke, the tumor preparation robot for hospital medication scenarios, and the world's first innovative drug for activated protein in hemophilia treatment will all make their debut...

上新的产品也彰显出盈康一生的医疗数智创新力。例如，全球第四代生物样本库生命方舟，首创"单体式+组合拼接式"自由拓展模式，在样本处理、转运、存储、质控、应用全流程均进行升级，可以精准实时管理每一份生物样本。

upward transition

From an industry trend perspective, Haier Group's foray into the big health sector is driven by its own considerations. After years of rapid development, the current home appliance industry has seen some categories entering a stock competition era, with the industry's ceiling already in sight.

Compared to the home appliance industry, the big health sector is not only a significant issue in national strategic planning but also possesses immense development potential. According to the "Healthy China" Planning Outline, by the year, the output value of China's health industry will reach trillions of yuan, and the big health industry will become one of the most promising industries in the 21st century. Market analysis reports from consulting firms indicate that the global medical device market is expected to grow to $1 trillion by the year. Consequently, companies like Haier Group have begun to view the big health track as a secondary growth curve.

In the wave of home appliance companies transitioning to the health industry, Haier Group has taken the lead. According to data released by Haier Group, the scale of its health sector has grown from billions of yuan in a certain year to billions of yuan in another year. In just a few years, Yingkang Life has evolved from a single hospital into a comprehensive health ecosystem, with its scale expanding nearly tenfold.

What is the secret behind the rapid scale transition? The core may lie in focusing on user needs.

At the recent (Third) Ecological Brand Conference, Yingkang Yisheng also revealed the logic behind its rapid growth. The company's spokesperson explained that in the doctor-patient relationship, "patient" refers to clinical and health needs, while "doctor" represents the supply of innovative technologies and solutions in the healthcare sector. However, in traditional scenarios, there is a lack of smooth communication and inefficient resource integration between the two. Yingkang Yisheng has innovatively proposed the "doctor-patient integration" model in the healthcare field, breaking down departmental boundaries.

At Shanghai Yongci Rehabilitation Hospital, traditional and complex department boundaries have been blurred, shifting from "patients running around departments" to "medical staff revolving around patients." Here, Yingkang Life helps various processes and nodes of the hospital achieve IoT, digitalization, and intelligence, enabling medical staff to accurately and in real-time understand patients' physical conditions and liberate them from time-consuming and labor-intensive tasks such as documentation, allowing them to spend more time with patients. The implemented "Yingkang Digital Human" patient-dedicated one-on-one service platform provides seamless service for patients before, during, and after their hospital stay.

Will the future usher in a "super evolution"?

More new evolutions are accelerating their implementation. For instance, Yingkang Yisheng, in collaboration with its ecosystem partners, has jointly established the medical engineering innovation industrialization platform "Haiyi Hui," which achieves co-creation and win-win outcomes through an ecosystem model of cross-border efficient collaboration. In the new iteration of the "Doctor-Patient Unity" version, ecosystem co-creation has become crucial.

The doctor has become a maker, and our makers have also become nodes in the hospital. According to the head of Yingkang Yisheng, currently, through the Haiyi Hui platform, the last mile of medical-engineering transformation can be effectively bridged. More importantly, it builds the first mile of medical-engineering transformation around clinical pain points. For example, in collaboration with the Capital Medical University and the Beijing Institute for Brain Disorders, a global pioneering project on cryogenic brain nerve protection technology transformation has been carried out, bringing good news to millions of stroke patients in China.

This eco-co-creation model has also extended to the sample management process in the field of big health. It is understood that Yingkang Yisheng has recently pioneered the Ark--℃ Intelligent Expandable Workstation, addressing the pain points of traditional sample management models relying on manual labor, which are prone to cumbersome operations, errors, difficulties in data information management, and risks of sample leakage and inactivation, hindering the application and transformation of biological sample resources and research data.

Carrying the mission of being Haier Group's second growth curve, Yingkang Yisheng, like a school of fish exploring the deep sea, continuously evolves and iterates itself in the changing market temperature, and may potentially achieve "super evolution" in the future.

For instance, after Haier strategically invested in Shanghai RAAS, the "expanding plasma" and "de-plasma" strategies implemented simultaneously laid the foundation for its super evolution in the blood products field.

Shanghai RAAS was originally just a blood products company. After Haier's strategic investment, the plan is to "expand the pool" and focus on developing more clinical indications and applications in the "coagulation and hemostasis" field, covering areas such as cardiology, gynecology, and surgery, to maintain a leading position. It is reported that with the support of Yingkang Life, Shanghai RAAS has advanced its expansion plan for the Fengxian Phase II park, increasing investment in digital and intelligent manufacturing while promoting capacity enhancement and meeting the growing demand for blood products, aiming to build a benchmark information-based and intelligent biotech industrial park in the industry.

Additionally, Shanghai RAAS's planned "de-starching" aims to further explore opportunities in the R&D pipeline of non-blood product fields such as recombinant proteins and cells, such as the prevention and treatment of early Alzheimer's disease, autoimmune diseases, and cardiovascular damage repair.